Taienkang (301263.SZ) subsidiary received a drug registration certificate for laberolol hydrochloride tablets

According to Zhitong Finance App, Taienkang (301263.SZ) announced that Shandong Huabo Kaisheng Biotechnology Co., Ltd. (“Huabo Kaisheng”), a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for laberol hydrochloride tablets issued by the State Drug Administration.

According to reports, laberol hydrochloride tablets are a commonly used alpha receptor and beta blocker. They achieve treatment goals by blocking adrenaline receptors, slowing sinus rhythm, and reducing peripheral vascular resistance. They are mainly used to treat various types of hypertension. As of the disclosure date of the announcement, after checking the website of the State Drug Administration, a total of 9 domestic companies for laberolol hydrochloride tablets had obtained drug registration approvals. Among them, only two varieties passed the consistency evaluation. The laberol hydrochloride tablets approved by Huabo Kaisheng are the second domestic variety to pass the consistency evaluation.